Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1960 1
1961 1
1964 2
1972 2
1974 2
1975 1
1976 1
1978 2
1980 1
1985 1
1986 1
1994 2
1995 2
1999 1
2000 1
2004 2
2005 1
2008 1
2014 1
2015 2
2016 2
2017 1
2018 1
2019 3
2021 2
2022 2
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Results by year

Filters applied: . Clear all
Page 1
Cell-penetrating and neurotargeting dendritic siRNA nanostructures.
Brunner K, Harder J, Halbach T, Willibald J, Spada F, Gnerlich F, Sparrer K, Beil A, Möckl L, Bräuchle C, Conzelmann KK, Carell T. Brunner K, et al. Among authors: beil a. Angew Chem Int Ed Engl. 2015 Feb 2;54(6):1946-9. doi: 10.1002/anie.201409803. Epub 2014 Dec 17. Angew Chem Int Ed Engl. 2015. PMID: 25522332
BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults.
Seidel A, Zanoni M, Groß R, Krnavek D, Erdemci-Evin S, von Maltitz P, Albers DPJ, Conzelmann C, Liu S, Weil T, Mayer B, Hoffmann M, Pöhlmann S, Beil A, Kroschel J, Kirchhoff F, Münch J, Müller JA. Seidel A, et al. Among authors: beil a. Front Immunol. 2022 Jul 25;13:882918. doi: 10.3389/fimmu.2022.882918. eCollection 2022. Front Immunol. 2022. PMID: 35958601 Free PMC article.
Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.
Groß R, Zanoni M, Seidel A, Conzelmann C, Gilg A, Krnavek D, Erdemci-Evin S, Mayer B, Hoffmann M, Pöhlmann S, Liu W, Hahn BH, Beil A, Kroschel J, Jahrsdörfer B, Schrezenmeier H, Kirchhoff F, Münch J, Müller JA. Groß R, et al. Among authors: beil a. EBioMedicine. 2022 Jan;75:103761. doi: 10.1016/j.ebiom.2021.103761. Epub 2021 Dec 17. EBioMedicine. 2022. PMID: 34929493 Free PMC article. Clinical Trial.
40 results